In Vivo CAR T-Cell Therapy: Revolutionizing Cancer Immunotherapy?
2025-05-27
CAR T-cell therapies have shown remarkable success in treating blood cancers, but their laborious ex vivo manufacturing and high cost limit their accessibility. To address these challenges, scientists are developing in vivo CAR T-cell therapies, which involve genetically engineering T cells directly within the body. This approach promises to simplify manufacturing, reduce costs, and benefit more patients. While in vivo methods face challenges like precise targeting of T cells and potential side effects, their potential is immense and could revolutionize cancer immunotherapy.